Finding 497942 (2023-004)

Material Weakness Repeat Finding
Requirement
H
Questioned Costs
$1
Year
2023
Accepted
2024-09-24

AI Summary

  • Core Issue: The organization failed to verify that costs were charged within the correct period of performance for federal awards, leading to a repeat finding from the previous year.
  • Impacted Requirements: Approximately $19,400 in questioned costs were identified due to improper billing practices, affecting compliance with federal funding regulations.
  • Recommended Follow-Up: Implement independent review procedures for grant period compliance and ensure documentation of this review is maintained to prevent future issues.

Finding Text

#2023-004 – Major Federal Award Finding – Period of Performance Nature of Finding: Compliance Finding – Period of Performance and Material Weakness in Internal Controls over Compliance This is a repeat of prior year finding #2022-004. Criteria/Condition: A non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award’s period of performance. The Organization did not have controls in place to verify that costs were being charged to the award in the correct period of performance. Questioned Costs: Approximately $19,400 Identification of How Questioned Costs Were Computed: A sample of 40 non-payroll expenditures totaling approximately $110,000 was selected from a population of approximately $175,000 of non-payroll expenditures charged to the major program during the year ending December 31, 2023. • Of the invoices selected for testing, 4 expenditures were billed during the month of September 2023. All 4 of these expenditures were inappropriately charged to the incorrect grant period. As a result, the questioned costs include all non-payroll expenditures billed in September 2023, which was approximately $15,700. • Of the 36 remaining invoices selected for testing, 6 other invoices were partially or entirely billed to the incorrect grant period, totaling an additional $2,582 identified error. Questioned costs are estimated by projecting this error identified in the sample tested to the population of non-payroll expenditures billed during the remaining 11 months of the year (excluding September 2023). Cause/Context: There are not proper controls in place to review invoices and assign them to the appropriate grant period. Seven expenditures out of forty non-payroll related expenditures tested for the grant were for contracted annual services or other costs that partially or entirely related to a separate performance period but was billed in its entirety to the current fiscal year. Effect: An overstatement of expenditures for the grant was reported in the current year. Reimbursement was sought for expenditures outside of the grant’s period of performance. Recommendation: We recommend procedures be established for the independent review of the grant period of performance when recording transactions and preparing grant reimbursement requests. Evidence of this review should be documented and maintained. Views of Responsible Officials and Planned Corrective Actions: MARR will retain a CPA consultant to establish formal written policy documenting significant accounting procedures including but not limited to the independent review of the grant period of performance when recording transactions and preparing grant reimbursement requests. Evidence of the review to be documented and maintained according to the procedures to be implemented.

Categories

Questioned Costs Period of Performance Allowable Costs / Cost Principles Cash Management Material Weakness Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 497935 2023-004
    Material Weakness Repeat
  • 497936 2023-005
    Material Weakness Repeat
  • 497937 2023-006
    Material Weakness Repeat
  • 497938 2023-007
    Material Weakness Repeat
  • 497939 2023-008
    Material Weakness Repeat
  • 497940 2023-009
    Material Weakness Repeat
  • 497941 2023-010
    Material Weakness Repeat
  • 497943 2023-005
    Material Weakness Repeat
  • 497944 2023-006
    Material Weakness Repeat
  • 497945 2023-007
    Material Weakness Repeat
  • 497946 2023-008
    Material Weakness Repeat
  • 497947 2023-009
    Material Weakness Repeat
  • 497948 2023-010
    Material Weakness Repeat
  • 1074377 2023-004
    Material Weakness Repeat
  • 1074378 2023-005
    Material Weakness Repeat
  • 1074379 2023-006
    Material Weakness Repeat
  • 1074380 2023-007
    Material Weakness Repeat
  • 1074381 2023-008
    Material Weakness Repeat
  • 1074382 2023-009
    Material Weakness Repeat
  • 1074383 2023-010
    Material Weakness Repeat
  • 1074384 2023-004
    Material Weakness Repeat
  • 1074385 2023-005
    Material Weakness Repeat
  • 1074386 2023-006
    Material Weakness Repeat
  • 1074387 2023-007
    Material Weakness Repeat
  • 1074388 2023-008
    Material Weakness Repeat
  • 1074389 2023-009
    Material Weakness Repeat
  • 1074390 2023-010
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $117,344
93.959 Block Grants for Prevention and Treatment of Substance Abuse $35,139